The U.S. and EU markets comprise approximately 32% of the global total addressable patient population and therefore the majority 68% is more insulated from mid-term competitive threats because of our global capabilities and market leadership. Third, our global commercial, medical and market access capabilities built over 20 years as just described. Fourth, the prioritization and acceleration of BMN 333, our long-acting CNP that leverages the same CNP as VOXZOGO and fifth, our plans to vigorously defend our intellectual property. In summary, we maintain our confidence in the long-term growth potential of our Skeletal Conditions franchise. Beyond Skeletal Conditions, our global Enzyme Therapies portfolio continued to perform well and grow in the third quarter with 27% revenue growth in Q3 and 13% year-to-date growth. Q3 Enzyme Therapies revenue benefited from increased ALDURAZYME revenue as we delivered a substantial amount of product to Sanofi (NASDAQ: SNY ) during the quarter.